Girls (n = 38) | Boys (n = 15) | P-valuea | |
---|---|---|---|
Age in years, Md (range) | 13 (8–18) | 15 (10–18) | 0.51 |
8–12 years, n (%) | 16 (42) | 5 (33) | |
13–18 years, n (%) | 22 (58) | 10 (67) | |
CHAQ Disability Index b, Md (range) | 0.50 (0–2.75) | 0.38 (0–1.38) | 0.65 |
Categories, n (%) | 0.56 | ||
None-mild | 12 (32) | 5 (33) | |
Mild-moderate | 9 (24) | 5 (33) | |
Moderate | 13 (34) | 5 (33) | |
Severe | 3 (8) | ||
Missing | 1 (3) | ||
Pain VAS c, 0–100 Md (range) | 32 (0–93) | 50 (0–99) | 0.50 |
Well-being VAS d, 0–100 Md (range) | 22 (0–99) | 27 (0–100) | 0.75 |
ILAR diagnosis e, n (%) | 0.01 | ||
Systemic arthritis | 1 (3) | 1 (7) | |
Oligoarthritis | 16 (42) | 3 (20) | |
Polyarticular arthritis, RFf-negative | 2 (5) | ||
Polyarticular arthritis, RFf-positive | 8 (21) | 1 (7) | |
Psoriatic arthritis | 6 (16) | ||
Enthesitis-related arthritis | 3 (8) | 5 (33) | |
Unspecified arthritis | 2 (5) | 5 (33) | |
Physical education participation, | |||
n (%) | 0.08 | ||
Always | 12 (32) | 9 (60) | |
Sometimes | 16 (42) | 4 (27) | |
Not at all | 6 (16) | 2 (13) | |
Not relevant | 3 (8) | ||
Missing | 1 (3) | ||
Disease duration in years Md (range) | 4.5 (0–16) | 3.0 (0–13) | 0.09 |
ESR g, mm/hour, Md (range) | 5 (2–31) | 4 (2–35) | 0.14 |
Disease activity categories, n (%) | 0.37 | ||
No | 13 (34) | 8 (53) | |
Low | 20 (53) | 5 (33) | |
Moderate | 4 (10) | 2 (13) | |
High | 0 | 0 | |
Missing | 1 (3) | 0 | |
Medication at study visit h, n (%) | |||
DMARD | 24 (63) | 7 (47) | 0.70 |
NSAID | 25 (66) | 8 (53) | 0.42 |
Biologic medication | 4 (10) | 0 | |
Corticosteroid therapy | 7 (18) | 0 | |
Eye drops/corticosteroid | 2 (5) | 0 |